secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protagonist Therapeutics, Inc (PTGX)
CIK:        0001377121
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0001104659-23-113828
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protagonist Q3 net loss $34.1M; earns $50M milestone from Janssen for JNJ-2113 Phase 3
--------------------------------------------------------------------------------

- Net loss of $34.1M ($0.58 per share) vs $31.2M loss in Q3 2022; R&D expenses rose to $30.7M.
- Cash, equivalents and marketable securities $322.7M as of Sep 30, 2023; cash runway through Q1 2026.
- JNJ-2113 Phase 3 ICONIC-LEAD, ICONIC-TOTAL trials and Phase 2b ANTHEM-UC trial initiated in Q4 2023.
- Dosing of third patient in ICONIC-LEAD triggered $50M milestone from Janssen in October 2023.
- Five rusfertide abstracts accepted for oral/poster presentations at ASH 2023 annual meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1377121/000110465923113828/0001104659-23-113828-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1377121/000110465923113828/tm2329667d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-113828

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer